Our mission.

We are translating breakthrough science into scalable novel therapeutics for high-burden infectious diseases with unmet needs, de-risking translation from bench to bedside and driving disciplined clinical and commercial execution with therapeutics to bring hope through to those who suffer in this world.

Clinical and regulatory expertise.

We bring together leadership with experience across clinical operations, translational research, regulatory validation, hospital systems, finance, and international program execution.

Clinical, regulatory, and commercial relationships are communicated through approved public disclosure.

Scientific, clinical, and operating leadership.

Scientific Board and the management team combine operating execution with specialist scientific, clinical, and translational expertise.

Yoo Seung Kim

Yoo Kim

Chief Executive Officer

Read more
  • Cross-sector executive leadership and venture development in AI-enabled healthcare.
  • Over 25 years of international experience spanning structural and infrastructure engineering, energy systems, and healthcare innovation.
  • CEO and Managing Partner of Macro HRD SG and CUIYC Pte. Ltd., Singapore; former CEO of Ecorntech, Inc. (USA).
  • Led large-scale international projects including the Barakah Nuclear Power Plant (UAE) and the Qatar National Food Security Program.
  • Named inventor on numerous U.S., Thai, and Chinese patents in AI-enabled healthcare, diagnostics, and material innovation.
  • Combines computational systems design with AI-enabled healthcare platforms, imaging analysis, and clinical risk modeling.
Kawinyarat Mardpiratchata

Kawinyarat Mardpiratchata

Chief Financial Officer

Read more
  • Corporate finance and investment strategy for healthcare and biotech ventures.
  • Over 25 years in global finance, innovation, and corporate strategy.
  • Led enterprise transformation, treasury, and shared services at PTT.
  • Experience in investment banking, M&A, and international finance.
  • Drives cross-border ventures, AI strategy, and institutional partnerships.
  • Oversees financial structuring and governance for large-scale initiatives.
Jaegu Kang

Jaegu Kang

Chief Medical Officer

Read more
  • Clinical oversight in emergency and regenerative medicine.
  • Expertise in regenerative medicine and stem-cell therapy; Director of K-Genocell Hospital and YumaStem Medical Group.
  • Hospital Director with global clinical leadership across Korea, China, and Southeast Asia.
  • Board-certified Emergency Medicine specialist with international licensure (Korea, USMLE, China, Vietnam).
  • Former director and chief physician across leading aesthetic and medical institutions.
  • Combines regenerative medicine, anti-aging, and hospital governance expertise.
Edward Sung

Edward Sung

Director, IR & Strategic Partnerships

Read more
  • Cross-border strategy, investor relations, and fundraising across biotechnology and healthcare.
  • Leads investor relations and fundraising; engages institutional and strategic investors and drives the company's capital-raising.
  • Facilitates international relationships among institutional investors, healthcare organizations, and strategic partners.
  • Director of Business Development driving social-impact ventures and operational scale for non-profit helping the marginalized.
  • Advisor on ICT strategy for government-level infrastructure projects.
  • Ex. Consultant at Logic Savant.
  • Ex. Consultant at spectrum college funding.
Nam-Joon Cho

Nam-Joon Cho

Scientific Board

Read more
  • Membrane-active antiviral peptide design for broad-spectrum, mutation-resistant therapeutics.
  • MRS-Singapore Chair Professor of Materials Science and Engineering, Nanyang Technological University.
  • Develops lipid envelope-disrupting (LEAD) peptides effective against enveloped viruses, validated in vitro and in vivo.
  • Integrates biophysical, computational, and virological approaches to membrane-active peptide engineering.
Veron Ramsuran

Veron Ramsuran

Scientific Board

Read more
  • Host genetic and epigenetic regulation of HLA expression in infectious disease.
  • Group Leader at KRISP, University of KwaZulu-Natal, South Africa.
  • Defines how HLA expression levels and epigenetic regulation shape HIV, TB, and COVID-19 outcomes.
  • Directs next-generation sequencing and translational bioinformatics across host, pathogen, and microbiome genomics.
  • Former PI and co-investigator on grants supported by the NIH and the Gates Foundation.
Rawiwan Charoensup

Rawiwan Charoensup

Scientific Board

Read more
  • Applies computational modeling to support drug discovery and therapeutic decision-making.
  • Brings translational expertise in natural-product pharmacology, bridging ethnomedicine, phytochemical characterization, and drug-screening methodologies to identify bioactive candidates from medicinal plants and natural sources.
Wim Vanden Berghe

Wim Vanden Berghe

Scientific Board

Read more
  • Epigenetic signaling and ferroptosis-based therapeutics in inflammation-aging disease.
  • Professor of Epigenetic Signaling, University of Antwerp, Belgium.
  • Targets cancer, cardiovascular, and neurodegenerative disease through redox and ferroptosis pathways.
  • Applies multi-omics screening of phytomedicinal compounds for precision-medicine biomarkers.
Wenbin Li

Wenbin Li

Scientific Board

Read more
  • Leading neuro-oncologist specializing in personalized glioma therapy, with experience overseeing 25 active and 50 total clinical trials.
  • Director of Oncology at Beijing Tiantan Hospital, leading first-in-human and multicenter clinical trials for high-grade glioma.
  • Expert in clinical neuro-oncology and immunotherapy, advancing precision treatment strategies for glioma patients worldwide.
Felix Xia

Felix Xia

Chief Financial Advisor

Read more
  • Former executive at DBS, HSBC, and Ant Group, with 18+ years of experience in banking and fintech.
  • Led cross-border payment and digital banking platforms serving millions of customers across Asia.
  • Expert in payment infrastructure, FX settlement, and large-scale financial technology transformation.
Alexander Min

Alexander Min

International M&A Advisor

Read more
  • International M&A Advisor.
  • Ex. PwC Strategy Consultant.
  • Ex Amgen Inc. M&A Specialist.
Kamlen Pillay

Kamlen Pillay

Managing Partner / In-house Physician

Read more
  • Plastic surgeon and founder-entrepreneur; Founder & CEO of INUVERSAL GROUP and Medical Director of Specialist Cosmetic Institutes (SCIN), Cape Town, South Africa.
  • Completed residency in Plastic Surgery at the University of Cape Town; surgical training across Orthopaedics, General Surgery, and Plastic Surgery on three continents.
  • Member of the World Society of Anti-Aging Medicine, the American Academy of Aesthetic Medicine, and the Aesthetic and Anti-Aging Medicine Society of South Africa.
  • Specialises in stem cell applications, Platelet-Rich Plasma (PRP) therapies, and advanced laser technologies in anti-aging and cosmetic medicine; over 20,000 non-surgical procedures performed.
Sairam Kumar

Sairam Kumar

Managing Partner / In-house Physician

Read more
  • Board Certified General and Developmental-Behavioral Pediatrician; Adjunct Clinical Assistant Professor of Pediatrics (Voluntary) at the Keck School of Medicine, University of Southern California (USC).
  • Trained in General Pediatrics at Brookdale Hospital, Brooklyn, NY; completed Developmental-Behavioral Pediatrics at Children's Hospital Los Angeles (CHLA)-USC; fellowship in Leadership in Neurodevelopmental Disabilities.
  • Current Developmental-Behavioral Pediatric Attending and clinical supervisor at CHLA's Behavioral Health Institute / Boone Fetter Clinic.
  • Clinical interests include early childhood development, Giftedness/2e, supporting children after crises and grief, and the intersection of complex neurodevelopmental disorders and behavioral health.
Mo Li

Mo Li

In-house Physician

Read more
  • Attending Neurosurgeon specialising in neuro-oncology and CAR-T cell immunotherapy; Doctor of Medicine (Neurosurgery) from the International Neuroscience Institute, Hannover Medical School, Germany.
  • Currently responsible for clinical trials at Shenzhen Lansheng Brain Hospital; former Postdoctoral Fellow at Capital Medical University and Shanghai Enterprise Postdoctoral Station.
  • Led the first domestically developed CAR-T cell pre-marketing key clinical trial in China and advanced the first new drug NDA for lymphoma cell therapy products.
  • International Medical Consultant at INC International Neurosurgeons Group; recipient of the Chinese National Fund for Doctorate in Germany and the Chinese Postdoctoral Overseas Talent Fund.
Yew Kong Ling

Yew Kong Ling

Managing Partner / Investment

Read more
  • Private equity investor specialising in mergers and acquisitions with over 20 years of experience in accounting, finance, securities brokerage, and corporate restructuring.
  • Executive Chairman and Managing Director of Firstlink Investments Corporation Limited (SGX-listed); Chairman of Moya Asia Ltd.; directorships across public and private companies in Singapore, Malaysia, China, and Hong Kong.
  • Bachelor of Commerce from Murdoch University, Western Australia; Member of CPA Australia.
  • Extensive cross-border capital markets, corporate governance, and large-scale financial restructuring expertise across Asia-Pacific.
Sarah In Sook Kim

Sarah In Sook Kim

Managing Partner / Investment

Read more
  • Cross-border business strategist, investor, and venture developer; Founder & CEO of multiple companies across technology, health & beauty, and wellness.
  • Strategic and financial advisor to AI technology ventures and KOSDAQ-listed companies; led cross-border investments and market expansion across Korea, Greater China, Southeast Asia, and the United States.
  • Holds MBA from the University of Chicago, MS in Genetics, and BS in Biology; combines entrepreneurial leadership with deep investment and M&A expertise.
  • Over 25 years of international experience in investment, corporate strategy, and healthcare innovation.
Tanapattsorn Maardthpiratch

Tanapattsorn Maardthpiratch

Head of AI Decision Architecture

Read more
  • Head of AI Decision Architecture at MACRO HRD SG Pte. Ltd.
  • Designs AI decision models and reasoning architectures for healthcare and regulated industries.
  • Leads the development of the GEDM (Governed Explainable Decision Modeling) platform and its AI applications across genomics, infectious diseases, and digital health.
  • Passionate about building AI that is transparent, explainable, and designed to support trusted decision-making.
  • Combines innovation, strategic thinking, and interdisciplinary collaboration to translate complex biomedical challenges into real-world AI solutions.
Meesue Kim

Meesue Kim

Software Engineer

Read more
  • MIT-educated Software Engineer with 3+ years of experience developing scalable backend and frontend systems; holds a BS in Computer Science and Electrical Engineering from the Massachusetts Institute of Technology.
  • Software Development Engineer I & II at Amazon (Seattle, 2022-2025); led high-impact retail projects generating billions in revenue, including a cart page redesign launched early across all devices for Prime Day.
  • Spearheaded technology migration to standardize data across platforms and collaborated across 5+ partner teams to ensure efficient code reuse and timely feature delivery; served as Tech Lead driving end-to-end project ownership.
  • Proficient in Python, Java, JavaScript, React, Node.js, Django, and D3; experience spans ML platform automation, API development, and full-stack system design.